Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
7.42
+0.10 (1.37%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Atara Biotherapeutics Revenue
In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth. Atara Biotherapeutics had revenue of $32.75M in the quarter ending December 31, 2024, with 670.30% growth.
Revenue (ttm)
$128.94M
Revenue Growth
+1,404.02%
P/S Ratio
0.43
Revenue / Employee
$842,745
Employees
153
Market Cap
43.47M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
ATRA News
- 7 weeks ago - Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - Business Wire
- 2 months ago - The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 2 months ago - The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 2 months ago - Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - PRNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 2 months ago - Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation - Accesswire
- 2 months ago - Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire